Please use this identifier to cite or link to this item: https://hdl.handle.net/10419/66549 
Year of Publication: 
2010
Citation: 
[Journal:] Intereconomics [ISSN:] 1613-964X [Volume:] 45 [Issue:] 1 [Publisher:] Springer [Place:] Heidelberg [Year:] 2010 [Pages:] 35-47
Publisher: 
Springer, Heidelberg
Abstract: 
This article examines a sample of German pharmaceutical firms to highlight the strategic reasons why firms participate in various intellectual property (IP) marketplaces, both proprietary (patents and copyrights) and non-proprietary (open source and non-patented technology). The obstacles that prevent these marketplaces from functioning efficiently are also investigated. The analysis suggests that IP policy must embrace all IP forms and must recognise that IP marketplaces do not work automatically but suffer many institutional failures.
Persistent Identifier of the first edition: 
Document Type: 
Article
Document Version: 
Published Version

Files in This Item:
File
Size
245.49 kB





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.